Bone morphogenetic protein receptor complex (BMPR complex)

The Bone morphogenetic protein (BMP) receptor complex is a heteromeric transmembrane signaling unit composed of Type I and Type II serine/threonine kinase receptors. Key components include Type I receptors such as BMPR1A (ALK3), BMPR1B (ALK6), and ACVR1 (ALK2), alongside Type II receptors like BMPR2, ACVR2A, and ACVR2B (UniProt P36894, Q13873). Upon binding of BMP ligands, the Type II receptor phosphorylates the Type I receptor, triggering the activation of SMAD1/5/8 proteins or non-canonical pathways like MAPK (PubMed: 27638852). This signaling cascade is essential for embryonic development, osteogenesis, and maintaining vascular integrity. Mutations in the complex are linked to severe pathologies; for instance, ACVR1 mutations cause Fibrodysplasia Ossificans Progressiva (FOP), while BMPR2 mutations are a primary cause of hereditary Pulmonary Arterial Hypertension (PAH) (PubMed: 11017070). Pharmacological intervention focuses on restoring signaling balance through ligand traps like Sotatercept or selective kinase inhibitors like Saracatinib (ClinicalTrials.gov: NCT04576988).

Other names

BMP receptorBone morphogenetic protein receptorsBMPRTGF-beta superfamily receptor complexBMPR1-BMPR2 complex

Ligand trapping to prevent receptor activation, small molecule inhibition of Type I receptor kinase activity, and modulation of downstream SMAD phosphorylation (pSMAD1/5/8).